Publication | Closed Access

First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group

Endocrine OncologyMetastatic Breast CancerBreast OncologyMedicineClinical TrialsGynecologyBreast CancerPharmacotherapyMenopauseOncologyExemestane Versus TamoxifenGynecology OncologyEndocrine-related CancerFirst ResultsMenopause Hormone Therapy